Description

Etopozid (etoposide) Concentrate for Infusions 20 mg/ml. 10 ml. (200 mg.) Vial №1

Ingredients

Active ingredient: Etoposide. Inactive ingredients may include citric acid, polysorbate 80, and sodium chloride.

Dosage

Dosage: The recommended dose of Etopozid concentrate for infusions is determined by the patient’s body surface area and the specific protocol used. It is administered intravenously by a healthcare professional.

Indications

Indications: Etopozid is indicated for the treatment of small cell lung cancer, testicular cancer, and other malignancies. It works by inhibiting topoisomerase II enzyme, leading to DNA damage in cancer cells.

Contraindications

Contraindications: Etopozid is contraindicated in patients with a known hypersensitivity to etoposide or any of the inactive ingredients in the formulation.

Directions

Administration: Etopozid concentrate for infusions should only be administered by healthcare professionals experienced in the use of cytotoxic chemotherapy.

Scientific Evidence

Etoposide, the active ingredient in Etopozid, has been extensively studied for its efficacy in various cancer types. Research has shown that etoposide disrupts DNA synthesis in cancer cells, leading to cell death. Clinical trials have demonstrated the effectiveness of etoposide in combination with other chemotherapeutic agents in improving overall survival rates in cancer patients.

Additional Information

It is important to monitor blood counts regularly during etoposide therapy to assess for potential bone marrow suppression. Patients should be closely monitored for signs of infection or bleeding. Etopozid may cause nausea, vomiting, and hair loss as common side effects.

Pharmacological Effects: Etoposide exerts its anticancer effects by inhibiting topoisomerase II enzyme, leading to DNA damage and cell death in rapidly dividing cancer cells. This mechanism makes it an essential component of many chemotherapy regimens.

Comparative Effectiveness: Etopozid has shown comparable effectiveness to other topoisomerase inhibitors in the treatment of various cancers. Its use in combination therapies has demonstrated improved outcomes in certain malignancies.